- Home
- BCYC vs ERAS Comparison
BCYC vs ERAS Comparison
Compare BCYC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- ERAS
- Stock Information
- Founded
- BCYC 2009
- ERAS 2018
- Country
- BCYC United Kingdom
- ERAS United States
- Employees
- BCYC N/A
- ERAS N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- BCYC Health Care
- ERAS Health Care
- Exchange
- BCYC Nasdaq
- ERAS Nasdaq
- Market Cap
- BCYC 529.8M
- ERAS 484.4M
- IPO Year
- BCYC 2019
- ERAS 2021
- Fundamental
- Price
- BCYC $7.10
- ERAS $1.60
- Analyst Decision
- BCYC Buy
- ERAS Strong Buy
- Analyst Count
- BCYC 12
- ERAS 6
- Target Price
- BCYC $22.91
- ERAS $4.50
- AVG Volume (30 Days)
- BCYC 261.8K
- ERAS 749.3K
- Earning Date
- BCYC 08-08-2025
- ERAS 08-12-2025
- Dividend Yield
- BCYC N/A
- ERAS N/A
- EPS Growth
- BCYC N/A
- ERAS N/A
- EPS
- BCYC N/A
- ERAS N/A
- Revenue
- BCYC $19,281,000.00
- ERAS N/A
- Revenue This Year
- BCYC $7.35
- ERAS N/A
- Revenue Next Year
- BCYC N/A
- ERAS N/A
- P/E Ratio
- BCYC N/A
- ERAS N/A
- Revenue Growth
- BCYC N/A
- ERAS N/A
- 52 Week Low
- BCYC $6.10
- ERAS $1.01
- 52 Week High
- BCYC $28.67
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- BCYC 37.11
- ERAS 55.28
- Support Level
- BCYC $7.25
- ERAS $1.44
- Resistance Level
- BCYC $7.68
- ERAS $1.68
- Average True Range (ATR)
- BCYC 0.42
- ERAS 0.11
- MACD
- BCYC -0.07
- ERAS 0.00
- Stochastic Oscillator
- BCYC 12.80
- ERAS 67.69
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.